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PREFACE
There are a lot of issues in the United States but the stigmatization of the mentally ill is
one often overseen. In writing this review, I hope to shine a spotlight on the current situation of
mental illness research and treatment, and how it is in desperate need of reform and funding.
Research has progressed to a point where biological etiology and pathophysiological explanation
can be made for many disorders.
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ABSTRACT
Christopher Angerhofer: A Biological Review of Mental Illness: An Overview of Genetics and
Pathophysiology of Addiction, Major Depression, and Schizophrenia
(Under the direction of Greg Heiberger)
Novel approaches in understanding mental illness present solutions to current issues in
treatment and diagnosis. With advancements in genetics and neurology, the etiology and
pathophysiology of mental illness is slowly unwrapping. In discovering biomarkers for
depression, addiction, and schizophrenia, the precision for preventing, diagnosing, and treating
these disorders increases. The aim of this paper is to review current research for addiction, major
depression, and schizophrenia in genetics and physiology, while also clarifying the need for
reclassifying mental illness as diseases with a pathophysiological basis, not syndromal,
idiopathic disorders. Mental illness is dynamic in that it encompasses both environmental and
biological factors, but research emphasis on the latter has potential to improve the treatment of
disorders, and possibly prevent them.
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INTRODUCTION
MENTAL ILLNESSS & SOCIETY
Despite the advances in modern
medicine over the last century,
understanding and treatment for mental
illness has remained rather stagnant[5].
Other areas of medicine have adopted a
proactive approach to deter the onset of
serious illnesses and disorders, while
developments in psychiatry have remained
primarily therapeutic. With recent advances
in genetics and neurology, research in
mental illness has progressed faster than
ever although, the dynamic nature of mental
illness has made this progress difficult.
Mental illness is not characterized by
biology alone and the influence of
environmental variables can make them
unpredictable[6].
Although research in this field has
progressed significantly, the burden of
mental illness is still present. Psychiatric
disorders require extensive care due to their
severity and frequency. Mental illness is
socially, economically, cognitively and
behaviorally detrimental. These illnesses
don’t affect just the individual, but also their
families and communities. In the United
States alone, nearly fifty percent of people
will be diagnosed with a mental illness in
their lifetime[7]. Without significant
changes in how mental illness is viewed and
treated, this is unlikely to change anytime
soon[8].
Mental illness is expensive to both
the individual and the community. In the
United States alone, the combined annual
costs of substance abuse and anxiety
disorders is estimated to be around $542
billion. This accounts for the cost of

criminal justice, medical, accidents, and loss
of earnings. In total, psychiatric illness
accounts for approximately 6.2% of the
nation’s health care expenditure. The
economic impact in the individual has been
difficult to determine, but in a door to door
survey conducted by the National
Comorbidity Survey Replication (NCS-R),
there is an estimated earning loss of $16,306
per individual with a serious mental illness
that accumulates to approximately $193.2
billion annually. This estimate is very
conservative in that it does not account for a
multitude of other factors. When including
factors such as disability benefits, public
housing, food stamps, etc. the actual
estimate is closer to $317 billion annually,
and this still doesn’t account for incarcerated
persons, comorbid conditions, or early
mortality related costs[8, 9].
Stigmatization plays a significant
role in the issues plaguing mental illness in
healthcare. The diagnosed contend with both
the disorder itself and the negative
connotation society has place on it[10].
There are two separate parameters to this
prejudice wherein stigmatization is selfinflicted as much as it is socially imposed.
Western and European cultures are infamous
for their stigmatization of mental illness
which often extends to even medical
professionals. Benevolence, fear and
exclusion, and authoritarianism are three
distinct traits that individuals diagnosed with
a mental illness often express due to this
stigmatization[6]. Insofar, the most effective
method in combatting this issue has been,
and will continue to be, education and
awareness[10].
While stigmatization poses a
significant social issue, cognition deficits are
typically more of an issue with severe
1|Page
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disorders like schizophrenia, though
problems are noted in more common
disorders as well[11]. These affects are
noted by a decline in working memory,
executive function, and attention and
information processing. Initial illness
coupled with lethargic medication
compound this issue. Thus, a major obstacle
for those with disorders is job retention and
the need for cognitive treatment and
rehabilitation to live normal lives[12].
Unfortunately, mental illnesses are
rising in adults, young adults and
adolescents, with significant increases in the
latter two[13] . The increasing incidence and
prevalence of mental illness will amplify the
issues discussed above. This is further
justified by figure one that shows emergency
department visits due to mental health have
increased as well[14]. Another ongoing
issue promising to heighten the severity of
this situation is the opioid epidemic that
plagues the United States. Comorbid
addiction is fairly common in serious mental
illnesses, with studies showing nearly 5060% of individuals with schizophrenia also
having a substance abuse issue[15]. Each
year, opioid related deaths increase in both
accidental overdosing and suicide related
deaths[16]. This trend shows a need to
increase research and funding in addiction
and depression to directly combat this
national epidemic. Though the main culprit
in this situation is the painkiller
hydrocodone, other psychoactive drugs have
been implicated as well. A new method of
treating addiction, depression and
schizophrenia is desperately needed.
Traditional pharmaceutical therapeutic
approaches work to some extent, but
antipsychotics can have severe side effects
with some long term use leading to
neurological issues like tardive

dyskinesia[17]. Through novel genotyping
and neuroimaging practices, precision
medicine can be practiced with psychiatric
diagnosis and care [5].

Figure 1. National trends in mental healthrelated emergency department visits per 1,000 U.S
population, by disorder category, 1992 to 2001[14].

DIAGNOSTIC ISSUES
Diagnosing mental disorders has
traditionally been done using the Diagnostic
and Statistical Manual of Mental Disorders
(DSM), which originated as a variant of the
International Classification of Diseases
(ICD), of which diagnose using a primarily
symptom-based approach. As of this review,
the manual stands on its fifth edition (DSMV) which was recently constructed in 2000
and published in 2013, has improved
immensely since its fruition in 1952[18].
Developed by the American Psychological
Association (APA), it is a classification
system that currently holds diagnostic for
297 conditions[18]. Significant changes
from the DSM-IV to the DSM-V include
nomenclature, a reworking of the multiaxial
system and the introduction of dimensional
assessments which is aimed at diagnosing
subtypes of disorders[19].
As science and research have
advanced, the DSM has been highlighted
with major criticisms with its nosology.
2|Page

A BIOLOGICAL REVIEW OF MENTAL ILLNESS
Until the most recent edition, diagnostic
criteria had been primarily description
based, almost entirely ignoring an etiologybased approach to mental illness. A major
criticism in development of the current DSM
structure is that the disorders it defines were
developed with little validity[20, 21].
Though the defining characteristics of
illness and disorders were developed with an
objective, empirical method of observation,
they stem from an almost entirely
psychoanalytic perspective and many fail to
account for the biological nature of mental
illness[22].

hole, the box canyon, and criticizes that the
criteria for diagnosis has been systematically
built upon instead of developing a new,
independent diagnostic tool. This method of
revision is in and of itself unscientific in that
it assumes the previous model of diagnosis
was correct. This evolutionary method of
nosology has constricted the understanding
of mental illness. The development of the
DSM-III in the 1980’s marked a noted
significant increase in the reliability of
diagnosis from both the DSM-I and DSM-II,
but it’s reliability has remained mostly
unchecked since[25].

This leads into the issue of a lack of
a disease progression system in psychiatric
healthcare. Most clinical pathologies are
defined and treated according to their
clinical stage of development. This works to
judge the severity of disease and provides a
better baseline in developing an effective
treatment strategy. This method of
evaluation has remained mostly absent in
psychiatric medicine to this day[23]. The
importance of such a structure comes into
play when attempting to prevent either
disease progression or regression. By
denoting a stage of severity in mental
illnesses, treatment strategies can be
developed that deter disease progression
through both biological and environmental
means. The prevention of regression in more
severe stages is another issue the current
diagnostic model fails to account for. In the
process of effective psychiatric treatment,
theses constructs are just as important as
they would be in other medical
pathologies[23].

This is all not to say the DSM should
be completely discarded, but that a new
approach should be researched that can
improve the efficacy of diagnosis and
treatment. A more pragmatic approach that
utilizes current scientific and clinical
technology to define mental illness should
be integrated into the current model. To fix
the box canyon problem, a new framework
must be built. The DSM is a starting point
and with the addition of genetics and
pathophysiology, treating mental illness can
be more effective[1].

Another significant issue with the
DSM is the “box canyon problem”[24]. This
problem analogizes that psychiatric
diagnosis has dug itself into an inescapable

MATERIAL AND METHODS
In writing this review, Web of
Science - All Databases and Google Scholar
were used for searching relevant research
articles. Wikipedia pages were used to gain
a basic understanding of some subject
material and to acquire additional references
and primary literature articles. To ensure
that the information this review provides is
accurate and relevant to the scientific
community, the vast majority of sources are
no older than the year 2000.
Keywords used in finding research
articles were; biomarkers, genetics, and
3|Page
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pathophysiology. Each of these was
searched in conjunction with the respective
disorders evaluated in this review.
Schizophrenia, depression, and addiction
were chosen as the three disorders in this
review due to promising research and shared
pathophysiological traits[26].

GENETICS
IDENTIFICATION METHODS
With the significant progression in
genotyping technology in the twenty-first
century and the completion of the Human
Genome Project in 2003, a new era of
medicine was born[27]. This new
technology has the potential to correlate
genetic variants with various psychiatric
disorders. Not only does this show promise
in a diagnostic capacity, but in therapeutic
one as well. Identification of common
markers for specific disorders can denote
which forms of treatment may be most
effective in a particular case. Medications
for treatment can then also be personalized
based on the individual’s genetic
architecture[27].
Psychiatric disorders presented many
issues in the first attempts to correlate genes
with illness. One of the first genotyping
methods using high-throughput sequencing
studied single nucleotide polymorphisms
(SNPs). Researchers quickly realized that
there could be a multitude of SNPs in one
gene and this method was abandoned as
technology wasn’t advanced enough to
provide timely results. Fortunately, the
concept of linkage disequilibrium (LD)
solved this issue in that only a portion of
SNPs need be mapped to determine common

structural variants (SV). This led to linkage
analyses that could test for rare mutations
with high penetrance and heritability in a
small population of alleles. Most linkage
analyses results reveal Mendelian
inheritance patterns[28].
As genotyping methods improved,
Genome-Wide Association Studies (GWAS)
became an invaluable tool that made
possible the mapping of millions of SNPs in
a genome of large populations of
individuals. Microarrays, and other
genotyping arrays, have allowed the
identification of common SV in association
with many mental disorders today. The main
drawback of GWAS is the phenomenon that
it is unable to prove strong heritability of
gene[29, 30].
Beyond the specific types of
genomic sequencing, a vital aspect to this
research is the methods by with the
information is obtained and interpreted.
Genetic research designs fall under two
categories; case-control or pedigree studies.
The first, which is most often utilized in
GWAS, looks for how many genetic
variations are present in a specific
population and then compares that number
to an appropriate control. This type of
design is simple and is efficient at
eradicating possible bias. The primary
limitation of case-control studies is the lack
of Mendelian genetics, and thus no ability to
discern de novo mutations[29].
Pedigree studies, following a specific
phenotype through family ancestry, can
achieve what case-control cannot and are
divided into the subcategories of simplex
and multiplex[31]. Simplex pedigree studies
compare an affected individual with
unaffected relatives. This case design has
4|Page
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been typically associated as the best method
of studying de novo mutations that correlate
with mental illness. Multiplex pedigree
studies are the most common form of
pedigree study and consist of phylogenic
study with multiple affected individuals of
relation. The primary reason for widespread
use is that high-penetrance mutations within
a family are can be linked for causation[29].

GENE ASSOCIATIONS
To date, there have been many
genetic associations made with various
mental illness. An important concept in this
research is that in identifying candidate
genes with mental illness associations, the
results are not going to lead to single variant
on one gene[29]. The interplay between
phenotype and genotype denotes that a

multitude of genes contribute to phenotype,
and this is especially true in the case of
mental illness. Therefore, early research that
yielded results in gene associations,
especially with schizophrenia, was met with
significant criticism because of the
complexity of genetics[2].
In the search for a genetic
association to mental disorders,
Schizophrenia has essentially stood as the
poster child for promising research. With a
heritability of approximately 80%, a genetic
component of schizophrenia was almost
certain[32]. Early results in this research
were met with criticism as duplication
efforts were seemingly unsuccessful due to
the presence of multiple alleles and

Table 1. Schizophrenia susceptibility genes and the strength of evidence in four domains. Most of the
identified loci are a result of linkage analyses[2].
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Table 2. Alcohol and nicotine addiction susceptibly genes, and their functions, identified in a Genome
Wide Association Study(GWAS)[3].

haplotypes[2]. As research and technology
progressed though, table one shows that
over a dozen genes have been implicated in
increased susceptibility for schizophrenia[2].
Fortunately, linkage analysis studies have
revealed that schizophrenia has a strong
genetic component. This has mostly been
attributed to the fact that multiple
susceptibility genes are found in linked
regions[2]. The high genetic heritability of
schizophrenia has made link analyses
particularly successful.
In studies attempting to discern gene
associations for major depression, results
have been slow and inconsistent. Very few
studies have actually been conducted, and
where they have, the sample sizes have not
been large enough to hold external
validity[33]. Despite these setbacks, recent
research has yielded promising results. In a
2010 study conducted in a Swedish
population-based cohort, four candidate

genes have been identified that show a
suggestive association with depression[34].
Use of the terminology “suggestive
association” is used by the authors to imply
that further research of these four candidate
genes is necessary to confirm their genetic
associations with major depression.
The epidemiology of depression has
always suggested that a strong genetic
component is involved[35]. As more
research is conducted on the genetics of
depression, results are indicating a high
percentage of heritability in nearly every
study[36]. Many recent studies have begun
to report a heritability of just under 80%,
which is similar to schizophrenia’s
heritability, while others have reported
lower stating that major depression involves
a genetic component of ~ 40%[36]. The
discrepancy in this research is most likely
attributed to the associated genes being
undetectable in linkage studies due to their
6|Page
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low effect size[33]. These results have
strengthened the assertion that major
depression is not solely based on one gene,
but interplay of several different loci.
Another obstacle in the quest to
delineate genes associated with major
depression is the heterogeneity of the
disorder. The polygenic nature of major
depression has commonly led to an overlap
in findings associated with the identification
of genetic determinants for other disorders.
These results indicate that formulating
specific subtypes of depression may yield
more accurate results when attempting to
search for associated genes[37].
Addiction encompasses a broad
category of mal-adaptive behaviors signified
by compulsive and uncontrollable substance
abuse or activity[3, 38, 39]. As one of the
most significant mental illness in society,
identifying associated genes is of utmost
importance in combating it. Addiction can
be further subdivided into the two categories
of behavioral addictions (e.g. gambling, sex,
shopping, etc.) and substance abuse
addictions. Both are relevant in this context
as genetic associations have been made in
each category[3].
Numerous candidate genes have
been identified for the various forms of
addiction. Table two outlines candidate
genes that have been identified in alcohol
and nicotine dependence[3]. The genes
listed above have shown the highest
association with these two types of
substance abuse, as confident replication in
identifying associated genes in other forms
of addiction has been notably lacking.
Currently, identified genes can also be
divided into two separate categories as well.
The first consists of substance specific

genes, and the second category consists of
genes identified with high risk behaviors,
such as impulsivity[3].
The heritability of addiction has been
extensively studied and results have
provided interesting insight into this
disorder. Rates of heritability differ from
substance to substance, but each hover
around 50%[40]. In further assessing the
genetic influence of addiction, stages of this
disorder show differing heritability. When
addiction is broken down into three stages of
initiation, chronic use, and addiction, the
effects of heritably are dependent on the
stage of the disorder. It is found to be
weakest during initiation and strongest in
last two stages[3].
A significant issue in researching
genetic associations of addiction is the high
amount of comorbidity present in this
disorder. Addiction is commonly comorbid
with other forms of addiction, as well as,
other mental illnesses[39]. An explanation
for high comorbidity is derived the from the
second category of associated genes,
discussed above, in that high-risk behavior
genes correlate with further maladaptive
behavior. As a result of this issue, research
into specific genetic associations in relation
to individual substances has been limited[3].

PATHOPHYSIOLOGY
ALTERED GENE EXPRESSION
Discovering genes associated with
psychiatric illness is important research but
knowing what those genes transcribe for is
the next step in making this research
clinically relevant. Genome wide gene
expression (GWGE) studies are a research
7|Page
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method similar to GWAS. Instead of
focusing on solely genetic architecture, and
the SVs therein, GWGE studies offer a
method of observing both DNA and RNA in
a hybrid model[28]. This method of research
is important in discerning the etiology of
diseases by comparing the expression of
mRNA between a control and experimental
group[28].

BIOMARKERS
Current research has been focused on
developing various novel methods to
diagnose psychiatric disorders[41-44].
While currently there is no certainty in
biological markers for diagnosis, progress is
being made and shows promise. Research is
taking multiple approaches in identifying
psychiatric disorders utilizing proteins
markers in easily accessible fluids, genetic

markers, and inflammatory markers such as
cytokines or hormones[41]. This type of
diagnosis allows for specific and
individualized care and has started to
redefine what is known about current
disorders. A prime example of this is the use
of motion-related Blood-oxygen-level
dependent (BOLD) signal effects in defining
subtypes of depression[45]. The
symptomatic diagnostic approach currently
in practice has led to a generalization of
symptoms that can defined by one or more
disorders, while research is showing that
mental illness can be more precisely defined
by pathophysiological abnormalities[46].
Due to the debilitating nature of
schizophrenia, there has been a significant
amount of research done in diagnosing this
disorder. The field of transcriptomics,
identifying genetic variations associated

Figure 2. Microglial activation hypothesis in the pathophysiology of schizophrenia. The left most column,
iNOS, DAMPS, Iba-1, and HSP70s, are examples of increased pro- inflammatory cytokines commonly seen in
schizophrenia. They activate M1 and M2 microglial cells, which in turn upregulate immune system effectors, IL-1β,
IL-6, TNF-α, and ROS, responsible for symptoms and pathophysiology associated with schizophrenia.
DAMPS=damage-associated molecular patterns; Iba-1=ionized calcium binding adaptor molecule 1; iNOS=nitric
oxide synthase; HSP70s=shock 70-kDa proteins; RAGE=glycation end-products receptor; ROS=reactive oxygen
species; TNF-a=tumor necrosis factor-a[4].
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with pathological illness, has shown
immense success in cancer research and
therefore, has taken the lead role in
identifying biomarkers associated with
schizophrenia[47]. Using gene ontology
enrichment studies, gene association to
function can be derived. Consistent with
other research, these studies have revealed a
relationship between altered metabolism,
neural development/function, and immune
response with schizophrenia pathology.
Figure two reveals a pathway in which the
immune system may play in the
pathogenesis of schizophrenia[4].
Like schizophrenia, inflammation
has also been indicated in major
depression[43]. When compared to
individuals without depression, both healthy
and unhealthy depressed individuals show
signs of inflammation. Symptoms of

depression appear to be side effects of the
upregulation of pro inflammatory which
have various effects on neurotransmitter
metabolism, neuroendocrine function, and
neural plasticity[43]. Notably, dopamine
synthesis and serotonin availability are
compromised in depressed individuals[43].
Another approach in identifying depression
has been using resting state fMRI (rsfMRI)
to recognize abnormalities in frontostriatal
and limbic brain networking[45]. Using this
method, researchers have been able to define
four subtypes of depression based on
abnormal connectivity[45]. This type of
research provides an additional avenue to
diagnosing and treating depression beside
the symptomatic descriptive method
currently used.
Research in identifying biomarkers
in addiction has been mostly concerned with

Table 3. Example of RDoC organization[1].
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the dopamine pathway[48, 49]. The most
consistent finding in addiction imaging is
the reduction of striatal D2 receptor binding
in individuals with addiction problems,
though reductions in D1 receptors have been
indicated also[48, 49]. The decreased
binding of dopamine in the striatal region
effects the circuitry of the prefrontal cortex
and therefore dysregulating impulsivity
control[49]. Therefore, mutations or
modifications to D2 receptors can actually
be predictive of addictive behavior[48].

PROSPECTIVE RESEARCH
NOVEL DIAGNOSTIC METHODS
A recent initiative to modify current
mental illness diagnosis has been dubbed the
Research Domain Criteria (RDoC), which
aims to take a more dynamic approach in
identifying mental illness by focusing on
biology-based criteria[1, 6]. The two current
diagnostic methods for identifying mental
illness are the Diagnostic and Statistical
Manual of Mental Disorders (DSM) and the
International Classification of Diseases
(ICD), both of which were developed before
modern neuroscience and thus do not
coincide nicely with some new findings in
this field[6]. Therefore, the National
Institute of Mental Health (NIMH) initiated
the RDoC to design a more comprehensive
diagnostic system that include genetics,
physiology, and neuroscience alongside
behavioral dimensions[1].
The RDoC, in its current state, is
more of a research database rather than a
diagnostic tool to be used in a clinical
setting[6, 50]. It is different from the
currently used diagnostic manuals in that it

is a matrix of information that can
continuously be modified as research
advances, similar to how the National
Database for Autism Research (NDAR) is
currently being used[6]. Table three shows
how the RDoC relates Domains/Constructs
to different measurable units where the
intersecting points will be filled with
research in that particular area[1]. The goal
of this research is to enter a new stage of
precision medicine for psychiatric
illnesses[50].
Clinical staging of mental illness
aims to adapt the same model of disease
progression associated with other clinical
pathologies to develop more specific
treatment regimens[23]. Using tools such as
the RDoC, psychiatric medicine can engage
in precision medicine that can specifically
target various stages of mental illness
progression. Staging is quite common in
other areas of medicine such as in cancer
and heart disease, yet this same ideology is
rarely applied to psychiatric illness[23, 51].
Disease staging has immense therapeutic
and preventative potential. By identifying
and utilizing biomarkers, mental illness can
be mapped into different stages of disease
progression based off of brain structure,
inflammation levels, and neuroendocrine
markers[52].

GENE & STEM CELL THERAPY
Discovering genetic and
physiological biomarkers for mental illness
opens the door for new treatment methods.
Moving beyond conventional
pharmacological remedies for mental
illnesses, both gene therapy and stem cell
therapy have had success in mouse models
treating different forms of mental illness. In
one study, researchers were able to reduce
depression-like behavior in mice with the
10 | P a g e
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administration of an adeno-associated virus
(AAV) into the nucleus accumbens to
restore p11 protein expression[53]. Humans
diagnosed with depression show low rates of
p11 expression and mice with a p11
knockout mutation show depressed
behavior, making this biomarker a good
candidate for gene therapy in treating
depression.
Researchers may have also
discovered a treatment for alcohol addiction.
Neuroinflammation, caused by chronic
ethanol intake and indicted as the cause for
perpetual alcohol use, was abolished in mice
with the administration of human
mesenchymal stem cells (hMSCs) into a
brain lateral ventricle[54]. The result of this
stem cell therapy is that within a 24hr
period, chronic alcohol consumption was
reduced by 70% and relapse-like alcohol use
was reduced by 80%. This study is another
example showing the potential effectiveness
of novel mental illness treatment strategies.

CONCLUSIONS
IMPLICATIONS
As research in psychiatry advances,
the etiology and pathophysiology of mental
illness clarifies. With this comes the ability
to develop prevention strategies based on
genetic heritability or provide specific
therapy to stop disorders from worsening.
Personalized medicine can be developed
based on the genotype of an individual and
this medicine can be used in a stage specific
manner depending of the severity of the
disorder. The biological component of
psychiatric medicine will benefit immensely
from this research, and combined with

proper psychotherapy, the goal lifelong
remission is one step closer for many.
While these medical advances in
psychiatry show promise, they may not be
welcome in some respects. The ethical
implications of a biological-based approach
to mental illness has many pros and cons to
take into consideration. Unexpected issues
that may arise are testing costs, reliability,
and discrimination[41]. As research in
genetics advances, the idea of genetic
existentialism often accompanies it, which is
the idea that we are simply nothing more
than what are genes code for[5]. This
ideology has both positive and negative
consequences. Genetic existentialism beliefs
can take responsibility off the patient for
having a mental illness, but at the same time,
studies have shown that it can lead to public
discrimination and self-stigmatizing [5].

LIMITATIONS
Small sample size is a consistent
issue in most genetic studies on mental
health. Finding a sample size that holds
external validity is difficult when
researching disorders that have low
incidence and prevalence, such as
schizophrenia.
When considering the etiology of
mental illness, environment plays much too
large of a role to be ignored. The complexity
of translation and transcription is further
multiplied due to the influence that
environmental stressors can have on gene
expression. Concentrating solely on one or
the other is not what this review endorses,
but to instead understand the various
influences that cause the manifestation of
mental illness.
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APPENDICIES
APPENDIX A
References are in APA format with
numbered citations. The majority of this
review’s style is based off UNC’s Graduate
Thesis/ Dissertation Guide, that can be
found at;
https://gradschool.unc.edu/academics/thesisdiss/guide/. A two-column format was
selected for consistency to coincide with the
other dissertations from the Human Biology
M.S. cohort of 2018.

regularly in my practice, it only provides
presently liver metabolic level information
and not molecule receptor specifics, still
remains a game changer in my practice. I
still hold out for germ line change of target
SNP's through viral vectors in my life
time...but one can only hope...and keep
researching.

APPENDIX B
Reviewer Feedback;
Like you, my prayer is that one day we will
understand the biological underpinnings of
schizophrenia, which has like 17 different
subtypes and proposed etiologies,
depression, my own personal demon, and
addictions...C.S. Lewis described alcohol or
gambling manias as problematic by
society, but we turn a blind eye to golfing or
shopping manias...yet the neurobiological
circuitry is the same...only societies
condemnation of one and blessing of other
determines need for research dollars.
DSM is not perfect, and we need biological
understanding of mental illnesses...but...until
you new minds solve this for us, the DSM
has improved our ability to talk, research,
and accurately...mostly, analyze the myriad
of symptoms afflicting our patients, and find
the constellation of symptoms best matching
a diagnosis...which accurately treats current
symptoms.
While I have whole heartedly embraced
pharmacogenomic testing and use it
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